We tested serum samples from blood donors by using first-, second-, and third-generation enzyme immunoassays or recombinant immunoblot assays. Second-and third-generation assays gave comparable results. Circulating hepatitis C virus RNA was found in a high proportion of reactive samples. A lack of reactivity or low-level reactivity predicted the absence of hepatitis C virus RNA in 100% of the cases. All 68 samples were also tested for the presence of HCV RNA by a nested PCR, using established procedures (6, 15). 
one second-generation recombinant immunoblot assay (RIBA-2; Ortho Diagnostics), one third-generation recombinant immunoblot assay (RIBA prototype 3.0; Ortho Diagnostics), and one third-generation Western blot (immunoblot) assay (Wellcozyme HCV Western blot; Wellcome). Samples with absorbencies of less than 10% below or above the cutoff value were considered indeterminate. In addition 20 serum samples from donors nonreactive in the anti-HCV EIA antibody screening assay but showing elevated serum alanine aminotransferase (ALT) levels were also included.
Sixty-eight samples were reactive in the first-generation and first-generation supplementary assays. The seroprevalence of 0.29% is comparable to that found by another Swiss blood transfusion center (4) . No donor had anamnestic or serological evidence of acute or chronic hepatitis B. Sixty-three samples (92.6%) were confirmed by the second supplementary assay (Table 1 ). All samples found positive when the second-and third-generation assays were used were included in these 63 samples. Twelve samples with discrepancies were found ( Table  2 ). All of the remaining 56 samples were reactive in all assays. A comparison of the serological results with histories, risk factors, and clinical characteristics has been published elsewhere (24) .
All 68 samples were also tested for the presence of HCV RNA by a nested PCR, using established procedures (6, 15) . (Table 3) . Table 4 shows the results for detection of HCV RNA in comparison to the anti-HCV antibody patterns found when the RIBA-2, RIBA-3, and Wellcozyme assays were used. The reactivity pattern of the RIBA-2 assay was interesting because reaction to the c22-3 antigen predicted the presence of circulating virus in 96.2% of samples, whereas its absence predicted absence of circulating virus in 100% of samples, a finding also noted by others (3, 7, 13, 18, 19, 23 1, 2, 14, 16, 20) .
The exclusion from blood donation of all donors with sera reactive in a second-or third-generation assay should be recommended, since because of the known fluctuation of HCV RNA levels (3), the few second-or third-generation assaypositive subjects without demonstrable HCV RNA might indeed still be infectious (9, 17) .
